Cooperative Agreement UF1AG060965

This Project Grant award from the National Institute on Aging (NIA), under the Aging Research federal grant program (CFDA 93.866), is supporting the evaluation of the safety, tolerability, and immunogenicity of an adjuvanted preventive dual AB/Tau vaccine, DUVAX, in healthy volunteers. The $499,754 award to Nuravax, Inc. will fund a Phase 1 study to investigate this novel Alzheimer's disease (AD) vaccine candidate that aims to inhibit both amyloid-beta (AB) and pathological tau aggregation,...

This Project Grant award, with a total funding amount of $431,750, was provided by the National Institute on Aging (NIA) under the Aging Research federal grant program (CFDA 93.866). The award is for the development and evaluation of a novel immuno-gene therapy approach using a single-chain fragment variable (scFv) derived from an anti-tau oligomeric complex 1 (TOC1) antibody. The key objectives are to: 1) generate and validate the TOC1-scFv-HaloTag-Proteasome Degradation Signal (PDS)...

The National Institute on Aging (NIA), under the Aging Research Federal Grant Program (CFDA 93.866), awarded a $9,781,240 Project Grant to the Institute For Molecular Medicine Inc. in California. The grant funds a multicenter Phase 1 clinical trial to evaluate the safety and immunogenicity of a preventive tau vaccine, AV-1980R/A, in cognitively unimpaired individuals at risk of Alzheimer's disease (preclinical stage). The project aims to develop an innovative immunotherapy approach for...

This Project Grant award of $1,257,528 from the National Institute on Aging (CFDA 93.866 - Aging Research) to Novoron Bioscience Inc. is focused on developing a platform to evaluate novel therapies designed to inhibit the propagation and aggregation of pathological tau protein, which is a key driver of Alzheimer's disease and other tauopathies. The platform will leverage human induced pluripotent stem cell (hiPSC)-derived neural organoids, including both wild-type and LRP1 knockout organoids, to...

The University of Texas Medical Branch at Galveston will research immunotherapy targeting tau aggregate polymorphs under a $4.02 million project grant from the National Institute on Aging's Aging Research program (CFDA 93.866). The three-year award will support determining the efficacy of four monoclonal antibodies in targeting disease-relevant tau oligomeric strains/polymorphs implicated in neurodegenerative tauopathies like Alzheimer's disease and frontotemporal lobar degeneration. Researchers...

This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $356,174 to The Regents of the University of California, San Francisco (UCSF) to conduct in vivo testing of structure-based vaccine candidates targeting Alzheimer's disease. The goal is to determine the efficacy of an active immunization strategy in preserving cognitive and neural function by slowing the formation of amyloid-beta or tau protein aggregation in the brain. The research will use...

This Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) provides $2,181,250 in funding to the Seattle Institute For Biomedical And Clinical Research to develop small molecule inhibitors of the MSUT2 protein as a potential therapeutic approach for treating tauopathy disorders such as frontotemporal lobar degeneration, Alzheimer's disease, and related conditions. The project aims to optimize potent and brain-penetrant MSUT2 inhibitors and demonstrate...

This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) to Jillion Therapeutics Inc. aims to identify small molecule compounds that can bind to and modify the biological behavior of tau protein, which is implicated in Alzheimer's disease and other neurodegenerative "tauopathies". The $496,373 award, spanning September 2024 to August 2025, will utilize the company's DNA-encoded library (DEL) drug discovery platform to screen a large chemical...

This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $499,879 to Oligomerix Inc. to conduct a 13-week oral gavage toxicity study of the drug OLX-07010 in beagle dogs, followed by a 4-week recovery period. The study aims to de-risk a planned 39-week toxicology study required by the FDA for future Phase 1b clinical trials of OLX-07010 in Alzheimer's disease patients. Completing this 13-week dog study will allow Oligomerix to extend the dosing...

This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) to Tauvision, Inc. provides $493,384 to develop an eyedrop-based, non-invasive diagnostic test for Alzheimer's disease. The project aims to optimize a fluorescent compound that can label pathological protein aggregates in the eye and be imaged using standard ophthalmology equipment, allowing for a direct measurement of central nervous system biomarkers. In Phase 1, the researchers will improve the...